Baxter hires CFO from Smith & Nephew

The FDA issued warning letters to Baxter International and Olympus Medical Systems for GMP and QSR violations. Baxter's Round Lake facility was cited for contamination risks, inadequate procedures, and recurring sterility issues. Olympus faced violations at six facilities, including failure to address known hazards and inadequate risk management. Both companies were advised to take corrective actions.

Baxter International (BAX) received an FDA warning letter for its Illinois facility, citing cross-contamination, inadequate sterilization, and inspection issues. Wolfe Research maintained a Peerperform rating, noting the stock trades below its fair value. Seven analysts revised earnings downward ahead of the company's upcoming earnings report. Despite the regulatory challenges, Baxter reported strong Q2 2026 results, exceeding earnings and revenue expectations, and raised its full-year outlook.

Baxter International (BAX) appointed John Rogers as CFO, with CEO Andrew Hider temporarily assuming CFO duties. Rogers brings cross-industry experience, potentially influencing capital allocation and reporting. Baxter aims for $12.4B revenue and $788.3M earnings by 2029, requiring 2.8% yearly revenue growth. The company recently launched a $600M tender offer for longer-dated notes, amending its credit agreement. Investors focus on margin stabilization and leverage.

Baxter said in SEC filings that interim CFO Anita Zielinski will leave in September. She will join Cardinal Health as chief accounting officer and SVP of finance on Nov. 5, with a $750,000 sign-on bonus and $1 million in time-vesting RSUs. Baxter has not named a successor. Baxter recently raised its full-year outlook to 3%-4% sales growth and adjusted EPS of $1.95-$2.15.

Baxter International shares rose about 19% this week after the company reported a Q2 earnings beat and raised full-year guidance, according to S&P Global Market Intelligence and Baxter. Q2 sales were $2.96B, up 5% year over year, and GAAP net income rose to $135M. Baxter now expects 2025 sales growth of 3% to 4% and adjusted EPS of $1.95 to $2.15.

Baxter International shares rose about 19% over the week after the company reported encouraging Q2 results. Baxter posted $2.96B revenue, up 5% year over year, and GAAP net income of $135M. Adjusted EPS was $0.56. Analysts expected $2.8B revenue and $0.37 adjusted EPS. Baxter raised FY guidance to 3%-4% sales growth and adjusted EPS of $1.95-$2.15.